Viaderma Stock Net Income
| VDRM Stock | USD 0.0004 0.0001 20.00% |
As of the 17th of February 2026, Viaderma has the Semi Deviation of 12.75, risk adjusted performance of 0.1704, and Coefficient Of Variation of 502.26. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Viaderma, as well as the relationship between them. Please validate Viaderma variance, as well as the relationship between the value at risk and skewness to decide if Viaderma is priced more or less accurately, providing market reflects its prevalent price of 4.0E-4 per share. As Viaderma appears to be a penny stock we also recommend to double-check its total risk alpha numbers.
Viaderma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Viaderma's valuation are provided below:Viaderma does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Viaderma |
Viaderma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Viaderma's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Viaderma.
| 11/19/2025 |
| 02/17/2026 |
If you would invest 0.00 in Viaderma on November 19, 2025 and sell it all today you would earn a total of 0.00 from holding Viaderma or generate 0.0% return on investment in Viaderma over 90 days. ViaDerma, Inc. operates as a specialty pharmaceutical company in the United States More
Viaderma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Viaderma's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Viaderma upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 43.46 | |||
| Information Ratio | 0.1968 | |||
| Maximum Drawdown | 150.0 | |||
| Value At Risk | (33.33) | |||
| Potential Upside | 100.0 |
Viaderma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Viaderma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Viaderma's standard deviation. In reality, there are many statistical measures that can use Viaderma historical prices to predict the future Viaderma's volatility.| Risk Adjusted Performance | 0.1704 | |||
| Jensen Alpha | 5.56 | |||
| Total Risk Alpha | 3.71 | |||
| Sortino Ratio | 0.1349 | |||
| Treynor Ratio | 0.9783 |
Viaderma February 17, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1704 | |||
| Market Risk Adjusted Performance | 0.9883 | |||
| Mean Deviation | 17.32 | |||
| Semi Deviation | 12.75 | |||
| Downside Deviation | 43.46 | |||
| Coefficient Of Variation | 502.26 | |||
| Standard Deviation | 29.81 | |||
| Variance | 888.39 | |||
| Information Ratio | 0.1968 | |||
| Jensen Alpha | 5.56 | |||
| Total Risk Alpha | 3.71 | |||
| Sortino Ratio | 0.1349 | |||
| Treynor Ratio | 0.9783 | |||
| Maximum Drawdown | 150.0 | |||
| Value At Risk | (33.33) | |||
| Potential Upside | 100.0 | |||
| Downside Variance | 1888.89 | |||
| Semi Variance | 162.61 | |||
| Expected Short fall | (69.44) | |||
| Skewness | 1.84 | |||
| Kurtosis | 4.5 |
Viaderma Backtested Returns
Viaderma is out of control given 3 months investment horizon. Viaderma owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.21, which indicates the firm had a 0.21 % return per unit of risk over the last 3 months. We were able to interpolate data for twenty-six different technical indicators, which can help you to evaluate if expected returns of 6.53% are justified by taking the suggested risk. Use Viaderma Risk Adjusted Performance of 0.1704, semi deviation of 12.75, and Coefficient Of Variation of 502.26 to evaluate company specific risk that cannot be diversified away. Viaderma holds a performance score of 16 on a scale of zero to a hundred. The entity has a beta of 6.06, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Viaderma will likely underperform. Use Viaderma jensen alpha and the relationship between the value at risk and price action indicator , to analyze future returns on Viaderma.
Auto-correlation | 0.72 |
Good predictability
Viaderma has good predictability. Overlapping area represents the amount of predictability between Viaderma time series from 19th of November 2025 to 3rd of January 2026 and 3rd of January 2026 to 17th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Viaderma price movement. The serial correlation of 0.72 indicates that around 72.0% of current Viaderma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.72 | |
| Spearman Rank Test | 0.83 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Viaderma reported net income of (1.52 Million). This is 100.44% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is 100.27% higher than that of the company.
Viaderma Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Viaderma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Viaderma could also be used in its relative valuation, which is a method of valuing Viaderma by comparing valuation metrics of similar companies.Viaderma is currently under evaluation in net income category among its peers.
Viaderma Fundamentals
| Return On Asset | -0.91 | |||
| Operating Margin | (13.28) % | |||
| Current Valuation | 6.18 M | |||
| Shares Outstanding | 137.32 K | |||
| Price To Earning | 0.03 X | |||
| Price To Book | 0 X | |||
| Price To Sales | 2.01 X | |||
| Revenue | 44.69 K | |||
| Gross Profit | 37.63 K | |||
| EBITDA | (592.43 K) | |||
| Net Income | (1.52 M) | |||
| Cash And Equivalents | 13.08 K | |||
| Debt To Equity | 20.90 % | |||
| Current Ratio | 0.29 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (167.36 K) | |||
| Earnings Per Share | 0.16 X | |||
| Beta | -0.42 | |||
| Market Capitalization | 82.27 K | |||
| Total Asset | 426.56 K | |||
| Retained Earnings | (7.38 M) | |||
| Working Capital | (445 K) | |||
| Current Asset | 185 K | |||
| Current Liabilities | 630 K | |||
| Z Score | -28.3 | |||
| Net Asset | 426.56 K |
About Viaderma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Viaderma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Viaderma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Viaderma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetOther Information on Investing in Viaderma Pink Sheet
Viaderma financial ratios help investors to determine whether Viaderma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Viaderma with respect to the benefits of owning Viaderma security.